Compare WNC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | VNDA |
|---|---|---|
| Founded | 1985 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.8M | 361.4M |
| IPO Year | 2009 | 2005 |
| Metric | WNC | VNDA |
|---|---|---|
| Price | $12.89 | $6.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $11.00 | ★ $14.90 |
| AVG Volume (30 Days) | ★ 976.1K | 905.2K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 179.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,027,489,000.00 | $216,105,000.00 |
| Revenue This Year | $10.65 | $21.35 |
| Revenue Next Year | $14.06 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.81 | 8.72 |
| 52 Week Low | $6.63 | $4.14 |
| 52 Week High | $14.32 | $9.91 |
| Indicator | WNC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 65.69 | 51.73 |
| Support Level | $8.34 | $5.97 |
| Resistance Level | $12.94 | $6.73 |
| Average True Range (ATR) | 0.71 | 0.21 |
| MACD | -0.16 | 0.07 |
| Stochastic Oscillator | 50.68 | 54.72 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.